Related Experiment Video
Updated: Jun 11, 2025
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
Remarkable pathological response to neoadjuvant tepotinib in lung adenocarcinoma with MET exon 14 skipping mutation:
Rongzhen Li1,2, Xiaoyan Liu1, Yan Xu1
1Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Abstract:
Mesenchymal-epithelial transition (MET) exon 14 (METex14) skipping mutation is a rare (3%-4%) driver mutation in non-small cell lung cancer (NSCLC). Tepotinib, a selective MET inhibitor, has shown promise in treating METex14 skipping-mutated NSCLC. However, its feasibility for perioperative application remains unclear. This report describes a 60-year-old man with stage IIIA (cT2N2M0) lung adenocarcinoma harboring a METex14 skipping mutation. After initial treatment with savolitinib was discontinued due to grade 4 transaminitis, the patient was switched to tepotinib, resulting in significant tumor regression. Six months later, further shrinkage was observed, and surgery revealed remarkable pathological response with no residual tumor in lymph nodes (ypT2N0M0, IB). Postoperative tepotinib continued, with no relapse at 6-month follow-up. This case highlights the potential of tepotinib as neoadjuvant therapy for resectable METex14 skipping-mutated NSCLC, warranting further clinical trials.
Insights
Tepotinib shows promise as a neoadjuvant therapy for non-small cell lung cancer (NSCLC) with MET exon 14 skipping mutations. This targeted treatment led to significant tumor regression and a remarkable pathological response in a resectable stage IIIA NSCLC patient.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Mesenchymal-epithelial transition (MET) exon 14 skipping mutations are rare but significant drivers in non-small cell lung cancer (NSCLC).
- Tepotinib, a selective MET inhibitor, demonstrates efficacy in advanced NSCLC with METex14 skipping mutations.
- The potential of tepotinib in the perioperative setting for NSCLC remains largely unexplored.
